Targeted delivery To neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion Method

Pharmaceutical Research

Volumn 28, Issue 9, 2011, Pages 2261-2272

  Adrian, Joanna E ^a,b   Wolf, Alexander ^b   Steinbach, Annette ^a   Rössler, Jochen ^b   Süss, Regine ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Dual asymmetric centrifugation; GD2antibody; Neuroblastoma; Post insertion technique; siRNA delivery

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2 ANTIBODY; LIPOSOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DUAL ASYMMETRIC CENTRIFUGATION; ENCAPSULATION; ENDOCYTOSIS; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIPOSOMAL GENE DELIVERY SYSTEM; NEUROBLASTOMA; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROL BASED POST INSERTION TECHNIQUE; VEGF A GENE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CENTRIFUGATION; DRUG COMPOUNDING; GANGLIOSIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STEROLS;

EID: 80054758401     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0457-y     Document Type: Article

References (25)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-8. (Pubitemid 32494397)
2. Tiemannand K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med. 2009;1:142-51.
3. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-53. (Pubitemid 47064567)
4. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111-4.
5. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008;68:9078-86.
6. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319:627-30. (Pubitemid 351197066)
7. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-60. (Pubitemid 40282557)
8. Hirsch M, Ziroli V, Helm M, Massing U. Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC). J Control Release. 2009;135:80-8.
9. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U. S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19:428-32. (Pubitemid 28076487)
10. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203-16. (Pubitemid 37328872)
11. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13:464-77.
12. Gantert M, Lewrick F, Adrian JE, Rossler J, Steenpass T, Schubert R, et al. Receptor-specific targeting with liposomes in vitro based on sterol-PEG (1300) anchors. Pharm Res. 2009;26:529-38.
13. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer. 1997;73:42-9. (Pubitemid 27445989)
14. Hettmer S, Ladisch S, Kaucic K. Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett. 2005;225:141-9. (Pubitemid 40732777)
15. Kazarian T, Jabbar AA, Wen FQ, Patel DA, Valentino LA. Gangliosides regulate tumor cell adhesion to collagen. Clin Exp Metastasis. 2003;20:311-9. (Pubitemid 36745659)
16. Navid F, Armstrong M, Barfield RC. Immune therapies for neuroblastoma. Cancer Biol Ther. 2009;8:874-82.
17. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003;63:3919-22. (Pubitemid 36917906)
18. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466-8.
19. Adrian JE, Morselt HW, Suss R, Barnert S, Kok JW, Asgeirsdottir SA, et al. Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells. J Control Release. 2010;144:341-9.
20. Adrian JE, Kamps JA, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, et al. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. Biochim Biophys Acta. 2007;1768:1430-9. (Pubitemid 46795479)
21. Tettamanti G. Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J. 2004;20:301-17. (Pubitemid 39024039)
22. Kowanetzand M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018-22. (Pubitemid 44453326)
23. Jakovljevic G, Culic S, Stepan J, Bonevski A, Seiwerth S. Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis. J Exp Clin Cancer Res. 2009;28:143.
24. Massing U, Cicko S, Ziroli V. Dual asymmetric centrifugation (DAC)-a new technique for liposome preparation. J Control Release. 2008;125:16-24. (Pubitemid 350198678)
25. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods: Mol Biol. 2008;440:15-33.